Mackenzie Financial Corp Exelixis, Inc. Transaction History
Mackenzie Financial Corp
- $66.8 Billion
- Q3 2024
A detailed history of Mackenzie Financial Corp transactions in Exelixis, Inc. stock. As of the latest transaction made, Mackenzie Financial Corp holds 403,538 shares of EXEL stock, worth $13.6 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
403,538
Previous 433,311
6.87%
Holding current value
$13.6 Million
Previous $9.74 Million
7.55%
% of portfolio
0.02%
Previous 0.02%
Shares
28 transactions
Others Institutions Holding EXEL
# of Institutions
502Shares Held
243MCall Options Held
2.54MPut Options Held
2.29M-
Black Rock Inc. New York, NY33.5MShares$1.13 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$988 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$856 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$518 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$386 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $10.8B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...